Dr Reddy’s Laboratories (DRL)has launched its generic Semaglutide injection in Canada, becoming among the first companies to introduce the product in the Canadian market following regulatory approval from Health Canada.
The company said it received the Notice of Compliance (NOC) from Health Canada on April 28, 2026, paving the way for the commercial launch. Canada has also become the first G7 nation to grant market authorisation for generic Semaglutide injection.
Focus on diabetes care
Dr Reddy’s said the once-weekly injectable therapy is indicated for adults with type 2 diabetes mellitus to improve glycemic control alongside diet and exercise.
The drug is being supplied as a sterile solution for subcutaneous injection in a pre-filled pen format and will be available in 2 mg/pen and 4 mg/pen strengths, each carrying Semaglutide at a concentration of 1.34 mg/ml.
According to the company, the 2 mg/pen variant is designed to administer 0.25 mg or 0.5 mg doses, while the 4 mg/pen format delivers 1 mg doses per injection.
Expanding GLP-1 footprint
Dr Reddy’s Laboratories, Chief Executive Officer, Erez Israeli, said.the launch underlines the company’s preparedness to rapidly expand patient access following regulatory clearance.
“ We are pleased to launch our generic Semaglutide Injection in Canada, within days of receiving Health Canada approval. The milestone highlights our readiness to serve the Canadian patients, supported by our deep expertise in complex drug and peptide development.”
The company’s established presence and market access capabilities in Canada would support wider availability of advanced and affordable GLP-1 therapies.
The Canada launch follows its recent India rollout of Semaglutide under the brand name Obeda and forms part of its broader strategy to expand GLP-1 therapies across multiple global markets.